Skip to main content
. 2020 Jul 28;12(8):2091. doi: 10.3390/cancers12082091

Figure 4.

Figure 4

PRMT5 inhibitor treatment is shown to further decrease cell viability in the KRAS mutant CRC cells by cell viability analysis. Quantified cell viability assay results show that PRMT5 inhibitor treatment affected a further 2.4-fold (p < 0.005) and 2.0-fold (p < 0.005) decrease in cell viability after 60 h of treatment with 1 µM & 10 µM PRMT5 inhibitor concentrations, respectively, in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells. Data are expressed as means + SD from three independent experiments using four CRC cell lines (2 KRAS mutant, 2 KRAS WT). Data for the individual cell lines can be seen in Figures S2 and S3. *** represents p < 0.005.